Physicians' Academy for Cardiovascular Education

20 years clinical use of GP IIb/IIIa receptor antagonists:What have we learned and where to go?

Sep. 1, 2014


 

Meeting report

As an educational service we provide educational resources such as videopresentations of the actual lectures and presented slides to view and download (as PDF) to our PACE members
 

View the video presentations

20 years clinical use of GP IIb/IIIa receptor antagonists

Prof J Wouter Jukema, Leiden, The Netherlands

5 minutes


When to use GPIIb/IIIa receptor antagonists: pre-, peri- or post MI intervention

Prof. Kurt Huber, Vienna, Austria 

20 minutes


Selective use of platelet glycoprotein IIb/IIIa inhibition

Prof. Jean-Philippe Collet, Paris, France

25 minutes


View & download presentation slides
 

Introduction 20 years clinical use of GP IIb/IIIa receptor antagonists

Presentation by prof. J Wouter Jukema, MD, Leiden, The Netherlands 


 

When to use GPIIb/IIIa receptor antagonists: pre-, peri- or post MI intervention? + case discussion

Presentation by prof. Kurt Huber, MD, Wilhelminen hospital,  Vienna, Austria 


 

Selective use of platelet glycoprotein IIb/IIIa inhibition + case discussion

Presentation by prof. Jean-Philippe Collet, MD, Department of Cardiology, Centre Hospitalier Universitaire Pitié-Salpêtrière , Paris, France 



 

Educational objectives of the symposium

The goal of this program were to summarize the knowledge with regard to peri- and post procedural management of MI, based on patient cases.

After attending this program, the clinician will be better able to: 

  • Understand the pathophysiology of acute MI with a focus on the mechanisms of platelet aggregation

  • Identify the role of GP IIb/IIIa inhibitors in ACS

  • Summarize the cumulative published clinical trial and registry data on the use of GP IIb/IIIa inhibitors in ACS patients undergoing PCI

  • Describe the outcomes of peri- and post procedural platelet inhibition in MI intervention

  • Discuss the selective use of GP IIb/IIIa inhibitors in international guidelines and in daily practice

  • Improve practical understanding of when and why to use GP IIb/IIIa inhibitors in ACS PCI patients

  • Discuss the future of antiplatelet therapies and their potential clinical implications

 

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards the European Accreditation for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Funding

Supported by an unrestricted educational grant from Lilly.  

In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.”